






ORIGINAL RESEARCH

Association between sinusitis and incident rheumatic diseases: a population-based study

Vanessa L Kronzer ¹, John M Davis,¹ Andrew C Hanson,² Jeffrey A Sparks ³, Elena Myasoedova ^{1,2}, Ali Duarte-Garcia,¹ Alicia M Hinze,¹ Ashima Makol,¹ Matthew J Koster,¹ Robert Vassallo,¹ Kenneth J Warrington ¹, Kerry Wright,¹ Cynthia S Crowson ^{1,3}

To cite: Kronzer VL, Davis JM, Hanson AC, *et al*. Association between sinusitis and incident rheumatic diseases: a population-based study. *RMD Open* 2024;**10**:e003622. doi:10.1136/rmdopen-2023-003622

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/rmdopen-2023-003622>).

Received 17 August 2023
Accepted 16 December 2023



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Mayo Clinic, Rochester, Minnesota, USA

²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA

³Harvard Medical School, Boston, Massachusetts, USA

Correspondence to

Dr Vanessa L Kronzer;
kronzer.vanessa@mayo.edu

ABSTRACT

Objectives To determine whether antecedent sinusitis is associated with incident rheumatic disease.

Methods This population-based case-control study included all individuals meeting classification criteria for rheumatic diseases between 1995 and 2014. We matched three controls to each case on age, sex and length of prior electronic health record history. The primary exposure was presence of sinusitis, ascertained by diagnosis codes (positive predictive value 96%). We fit logistic regression models to estimate ORs for incident rheumatic diseases and disease groups, adjusted for confounders.

Results We identified 1729 incident rheumatic disease cases and 5187 matched controls (mean age 63, 67% women, median 14 years electronic health record history). After adjustment, preceding sinusitis was associated with increased risk of several rheumatic diseases, including antiphospholipid syndrome (OR 7.0, 95% CI 1.8 to 27), Sjögren's disease (OR 2.4, 95% CI 1.1 to 5.3), vasculitis (OR 1.4, 95% CI 1.1 to 1.9) and polymyalgia rheumatica (OR 1.4, 95% CI 1.0 to 2.0). Acute sinusitis was also associated with increased risk of seronegative rheumatoid arthritis (OR 1.8, 95% CI 1.1 to 3.1). Sinusitis was most associated with any rheumatic disease in the 5–10 years before disease onset (OR 1.7, 95% CI 1.3 to 2.3). Individuals with seven or more codes for sinusitis had the highest risk for rheumatic disease (OR 1.7, 95% CI 1.3 to 2.4). In addition, the association between sinusitis and incident rheumatic diseases showed the highest point estimates for never smokers (OR 1.7, 95% CI 1.3 to 2.2).

Conclusions Preceding sinusitis is associated with increased incidence of rheumatic diseases, suggesting a possible role for sinus inflammation in their pathogenesis.

INTRODUCTION

Respiratory irritants such as cigarette smoking have been associated with development of nearly all autoimmune rheumatic diseases including ankylosing spondylitis (AS),¹ giant cell arteritis (GCA),² myositis,³ psoriatic arthritis (PsA),⁴ rheumatoid arthritis (RA)⁵ and systemic lupus erythematosus (SLE).⁶

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Respiratory irritants are associated with incidence of many rheumatic diseases.

WHAT THIS STUDY ADDS

⇒ In this population-based case-control study, preceding sinusitis was associated with 1.4-fold increased odds of any rheumatic disease, especially antiphospholipid syndrome (7.0-fold increased odds) and Sjögren's disease (2.4-fold increased odds). In general, the association was strongest in the 5–10 years before disease onset and increased in a dose-response fashion with the number of sinusitis codes.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ Sinusitis may play a role in the pathogenesis of rheumatic diseases. Therefore, it represents a novel potential target for disease prevention and/or treatment.

Silica exposure has also been associated with several rheumatic diseases including vasculitis,⁷ RA,⁸ SLE⁹ and systemic sclerosis (SSc).¹⁰ Many other diverse forms of pulmonary irritation are associated with RA pathogenesis including air pollutants,¹¹ occupational inhalational exposures¹² and respiratory tract diseases.¹³

Building off this prior work, we recently identified an association of upper respiratory tract diseases such as sinusitis with increased risk of incident seropositive and seronegative RA.¹⁴ This association was strongest in the 5–10 years before RA onset, where acute sinusitis was associated with fourfold increased risk of RA.¹⁵ This association is plausible given the known association between sinusitis and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.¹⁶ Furthermore upper respiratory tract diseases are associated with

incident myositis,¹⁷ and infections are associated with GCA,^{18 19} Sjögren's disease²⁰ and SLE.²¹ Despite all of this evidence, the association between sinusitis and rheumatic diseases other than RA and ANCA-associated vasculitis remains unstudied.

To address this gap, we first aimed to determine the association between preceding history of sinusitis and later incidence of rheumatic diseases. Second, we aimed to determine the association between the timing of sinusitis and incidence of rheumatic diseases. We hypothesised that sinusitis is associated with an increased risk of most rheumatic diseases, especially in the 5–10 years before disease onset and for GCA, Sjögren's and SLE given their previously identified association with infections.

METHODS

Study design and participants

This population-based case–control study leveraged the Rochester Epidemiology Project (REP), a medical records-linkage system of over 500 000 unique individuals who resided in Olmsted County, Minnesota at some point between 1966 and the present.²² This study included adult subjects from the start of the electronic health record (EHR) in on 1 January 1995 until 12 December 2014—the last date where all REP rheumatic disease cohorts were updated. To allow ample time for exposure accrual, we a priori restricted the primary analysis to individuals with at least 7 years of EHR data before the index date of rheumatic disease criteria fulfilment or matched date for controls. This study complies with the Declaration of Helsinki.

Patient and public involvement

Patients and the public were involved in the creation of the REP but were not involved in the design or conduct of this particular analysis.

Incident rheumatic disease cases

All individuals with incident rheumatic diseases in this study met published classification criteria for ANCA-associated vasculitis,²³ primary or secondary antiphospholipid syndrome (APS),²⁴ AS,²⁵ dermatomyositis,²⁶ GCA,²⁷ mixed connective tissue disease (MCTD),²⁸ polymyalgia rheumatica (PMR),²⁹ PsA,³⁰ RA³¹ or SLE.³² The two exceptions were Sjögren's disease (due to the low frequency of lip biopsy) and SSc, which were based on physician diagnosis.^{33 34} We studied any disease with at least 20 subjects individually. We also combined all these diseases into standard disease groups including systemic autoimmune rheumatic disease (APS, dermatomyositis, MCTD, SLE, Sjögren's disease, SSc, spondyloarthritis (AS and PsA) and vasculitis (ANCA, GCA and PMR). We defined seropositive RA as positive rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (CCP) antibodies. Individuals that met criteria for more than one rheumatic disease were included only in the disease cohort where they first met criteria.

Controls

We matched each incident rheumatic disease case to three controls based on age (± 5 years) at index date, sex and length of prior EHR history (± 3 years). As for cases, we required that controls have at least 7 years EHR data. We also required controls to have no diagnosis codes for any rheumatic disease, as shown in eTable 1 in the supplement online supplemental file S1.^{23 35}

Sinusitis exposures

The primary exposure for this study was presence of any sinusitis (also subdividing into acute and chronic sinusitis). To reduce the likelihood of reverse causation, we required sinusitis to occur at least 1-year prior to index date. We ascertained presence of sinusitis using International Classification of Diseases (ICD) diagnosis codes for acute (ICD-9 461) or chronic (ICD-9 473) sinusitis, as described previously.^{14 15} The secondary exposure of interest was timing of the first occurrence of sinusitis, defined as the date of meeting the above exposure criteria. We subdivided these durations into >1 to 5 years, 5 to 10 years and >10 years. The reference or 'unexposed' group throughout this study consisted of the individuals with no sinusitis code of any kind between 1 January 1995 and the index date.

Our previous study in the Mass General Brigham Biobank showed the above definitions for acute and chronic sinusitis had a positive predictive value (PPV) of 96% and 88% by physician diagnosis and 80% and 62% by gold standard published criteria,^{36 37} respectively.¹⁴ We performed a separate validation in the REP using 50 randomly selected study subjects with sinusitis exposure (25 acute and 25 chronic sinusitis). Once again, we used physician diagnosis as the reference standard and validated these definitions by published criteria.^{36 37}

Covariates

We chose covariates based on prior association with rheumatic diseases and obtained them from the EHR's patient provided information. These included age at index date (continuous), sex (male, female), length of EHR history prior to index date (continuous), race and ethnicity (Asian, black, Hispanic (regardless of race), white, other/not reported), body mass index (BMI) at index date (continuous) and smoking status at index date (never, past, current). We obtained RA serostatus from EHR laboratory data. Missing BMI, smoking status and RA serostatus were imputed using 25 multiple imputed data sets. No subjects were missing any other data.

Statistical analysis

We summarised categorical variables as frequencies and continuous variables as means or medians. To estimate the association between sinusitis and rheumatic disease, we fit multivariable conditional logistic regression models. These models estimated ORs with 95% CIs for each rheumatic disease and disease group associated with sinusitis exposure (any, acute and chronic). Models were

adjusted for age, sex, EHR history, race and ethnicity, BMI and smoking status, as long as at least 56 rheumatic disease outcomes were present.³⁸ If not, we reported estimates from unadjusted conditional logistic models (conditioned on matching factors). To estimate the association between timing of sinusitis and each rheumatic disease, we fit the same models above but with the time window of first sinusitis exposure (>1 to 5 years, >5 to 10 years and >10 years) as the exposure.

We also performed three sensitivity analyses. First, we relaxed the 7-year EHR history requirement to only 3 years. Second, to determine if the burden of sinusitis was associated with each rheumatic disease, we repeated the above models with the number of qualifying sinusitis codes (1–3, 4–6 or 7+) as the exposure of interest. Third, given the strong association between smoking and many of the rheumatic diseases we studied, we estimated the association between sinusitis and disease according to smoking status (ever vs never) in pre-planned interaction analyses. Throughout this study, we used a significance threshold of two-sided $\alpha=0.05$. We prespecified all analyses in a study protocol. All analyses were conducted using R V.4.1.2 (R Foundation for Statistical Computing, Vienna, Austria) and SAS V.9.4 (SAS Institute, Cary, North Carolina, USA).

RESULTS

Cohort characteristics

This study included 1729 incident rheumatic disease cases and 5187 matched controls (mean age 63, 67% women and median EHR history duration 14 years in both groups). The median duration from first sinusitis code to index date of rheumatic disease criteria fulfilment was 7.7 years (IQR 4.3–10.7). Sinusitis codes had a 96% PPV (96% acute; 96% chronic) by physician diagnosis and 60% PPV (68% acute; 52% chronic) by gold-standard published criteria. The most common rheumatic disease in this cohort was RA (n=688), followed by PMR (n=610, [table 1](#)), whereas the least common were dermatomyositis (n=12) and MCTD (n=16). Among RA cases, 452 (66%) were seropositive, 234 (34%) were seronegative and 2 (0.3%) were unknown. The only other missing data among cases and controls were BMI in 226 (3.3%) and smoking status in 273 (3.9%).

Sinusitis and incident rheumatic disease

In multivariable analysis, history of sinusitis was associated with increased risk of any incident rheumatic disease (OR 1.4, 95% CI 1.2 to 1.7, [table 2](#)). This association was strongest for systemic autoimmune rheumatic diseases such as APS (OR 7.0, 95% CI 1.8 to 27) and Sjögren's disease (OR 2.4, 95% CI 1.1 to 5.3), but also present for PMR (OR 1.4, 95% CI 1.0 to 2.0, [table 2](#)). Acute sinusitis also showed a significant association with seronegative RA (OR 1.8, 95% CI 1.1 to 3.1). A sensitivity analysis repeating the above results but relaxing the EHR history requirement to only 3 years produced nearly identical

results (eTable 2 in the supplement online supplemental file 1).

Association by timing of sinusitis

The association between sinusitis and incident rheumatic disease showed the strongest point estimates in the 5–10 years before rheumatic disease onset (OR 1.7, 95% CI 1.3 to 2.3, [table 3](#)). Acute sinusitis was associated with any rheumatic disease only in the 5–10 years before disease onset (OR 1.6, 95% CI 1.1 to 2.3), whereas chronic sinusitis was associated in both the 1–5 years (OR 1.9, 95% CI 1.3 to 2.7) and 5–10 years (OR 1.8, 95% CI 1.3 to 2.5) before rheumatic disease onset. This stronger association between sinusitis and rheumatic diseases in the 5–10 years window before disease was especially evident for Sjögren's disease (OR 3.2, 95% CI 1.1 to 9.5) and PMR (OR 2.0, 95% CI 1.3 to 3.2, [table 3](#)). In contrast, sinusitis showed a stronger association with APS and RA in the 1–5 years before disease onset ([table 3](#)).

Association by number of sinusitis codes

The number of sinusitis codes showed a statistically significant dose-response relationship with incidence of rheumatic disease ([table 4](#)). For example, individuals with seven or more codes for sinusitis had strongly elevated risk for incident systemic autoimmune rheumatic disease (OR 4.8, 95% CI 1.7 to 13), Sjögren's disease (OR 8.7, 95% CI 1.4 to 52) and vasculitis (OR 2.0, 95% CI 1.2 to 3.4). Acute sinusitis also showed a significant dose-response association for seronegative RA (OR 0.8, 95% CI 0.3 to 2.1 for 1–2 codes, OR 1.9, 95% CI 0.8 to 4.0 for 3–4 codes and OR 4.3, 95% CI 1.6 to 11 for 5+ codes, $p=0.01$).

Association by smoking status

The association between sinusitis and any incident rheumatic disease showed a higher point estimate for never smokers (OR 1.7, 95% CI 1.3 to 2.2) compared with ever smokers (OR 1.2, 95% CI 1.0 to 1.6, [table 5](#)), though this difference was not statistically significant ($p=0.06$). Indeed, sinusitis was associated with higher point estimates among never smokers in most individual rheumatic diseases and disease groups ([table 5](#)), including RA (OR 1.6, 95% CI 1.1 to 2.4 for never smokers, OR 1.1, 95% CI 0.8 to 1.5 for ever smokers). Sjögren's disease was the only disease where sinusitis was statistically significantly associated in ever smokers (OR 2.9, 95% CI 1.0 to 8.2) but not in never smokers (OR 2.1, 95% CI 0.7 to 6.1).

DISCUSSION

In this population-based cohort of incident rheumatic disease cases and controls, preceding sinusitis was associated with increased risk of multiple incident rheumatic diseases, especially APS and Sjögren's disease. In general, the association between sinusitis and rheumatic diseases was strongest in the 5–10 years before disease onset and increased in a dose-response fashion with the number of sinusitis codes. Finally, the association between sinusitis and rheumatic disease was stronger among never

Table 1 Characteristics of the 1729 incident rheumatic disease cases in the Rochester Epidemiology Project with at least 7 years EHR history

Characteristic	ANCA vasculitis (n=38)	Ankylosing spondylitis (n=22)	APS (n=26)	Giant cell arteritis (n=79)	PMR (n=610)	Psoriatic arthritis (n=91)	RA (n=688)	Sjögren's syndrome (n=74)	SLE (n=44)	Systemic sclerosis (n=29)	All cases (n=1729)	Controls (n=5187)
Age, years, mean (SD)	60 (16)	35 (10)	59 (17)	78 (9)	74 (9)	47 (11)	57 (15)	61 (15)	50 (18)	60 (15)	63 (16)	63 (16)
Female sex, n (%)	18 (47)	9 (41)	13 (50)	60 (76)	390 (64)	40 (44)	479 (70)	60 (81)	34 (77)	25 (86)	1151 (67)	3453 (67)
EHR history, years, median (IQR)	13 (10–17)	11 (8–12)	12 (9–16)	14 (11–17)	13 (10–16)	13 (9–16)	15 (11–17)	12 (10–16)	16 (12–18)	13 (11–16)	14 (10–17)	14 (10–7)
Race and ethnicity, n (%)												
Asian	0 (0)	2 (9)	0 (0)	0 (0)	10 (2)	2 (2)	18 (3)	0 (0)	0 (0)	2 (7)	34 (2)	130 (3)
Black	0 (0)	0 (0)	0 (0)	0 (0)	5 (1)	3 (3)	10 (1)	1 (1)	1 (2)	0 (0)	20 (1)	87 (2)
Hispanic	1 (3)	2 (9)	0 (0)	1 (1)	11 (2)	5 (5)	26 (4)	3 (4)	1 (2)	0 (0)	50 (3)	161 (3)
White	34 (89)	18 (82)	25 (96)	78 (99)	577 (95)	80 (88)	629 (91)	70 (95)	41 (93)	25 (86)	1605 (93)	4718 (91)
Other/not reported	3 (8)	0 (0)	1 (4)	0 (0)	7 (1)	1 (1)	5 (1)	0 (0)	1 (2)	2 (7)	20 (1)	91 (2)
BMI, kg/m ² , median (IQR)	27 (24–32)	26 (24–31)	29 (25–33)	26 (22–29)	28 (25–31)	31 (27–35)	29 (25–33)	26 (22–32)	30 (26–34)	28 (24–31)	28 (35–32)	28 (24–32)
Smoking status, n (%)												
Never	9 (26)	12 (57)	11 (42)	36 (46)	263 (44)	29 (32)	249 (37)	30 (41)	14 (33)	8 (29)	676 (40)	2161 (44)
Past	21 (60)	5 (24)	10 (38)	39 (50)	291 (48)	41 (46)	284 (43)	39 (53)	13 (31)	14 (50)	769 (46)	2136 (43)
Current	5 (14)	4 (19)	5 (19)	3 (4)	48 (8)	20 (22)	134 (20)	4 (5)	15 (36)	6 (21)	245 (14)	656 (13)

*At index date of criteria fulfillment. ANCA, antineutrophil cytoplasmic antibody; APS, antiphospholipid syndrome; BMI, body mass index; EHR, electronic health record; kg, kilograms; m, metres; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.

Table 2 Association between preceding sinusitis and incident rheumatic disease

Rheumatic disease	Any sinusitis, n (%)		Adjusted OR* for rheumatic disease by exposure		
	Cases	Controls	Any sinusitis (n=6916)	Acute sinusitis (n=6432)	Chronic sinusitis (n=6413)
Any rheumatic disease	229 (13)	503 (10)	1.4 (1.2 to 1.7)	1.4 (1.1 to 1.7)	1.6 (1.3 to 1.9)
Rheumatoid arthritis	97 (14)	235 (11)	1.3 (1.0 to 1.6)	1.2 (0.9 to 1.7)	1.3 (0.9 to 1.8)
Seropositive	61 (13)	160 (12)	1.2 (0.8 to 1.6)	1.0 (0.7 to 1.5)	1.3 (0.8 to 1.9)
Seronegative	36 (15)	75 (11)	1.5 (1.0 to 2.3)	1.8 (1.1 to 3.1)	1.3 (0.7 to 2.3)
Spondyloarthritis	17 (15)	37 (11)	1.3 (0.7 to 2.5)	1.5 (0.7 to 3.0)	1.3 (0.6 to 2.9)
Ankylosing spondylitis [†]	5 (23)	8 (12)	2.4 (0.6 to 9.2)	2.2 (0.5 to 9.0)	8.6 (0.9 to 79)
Psoriatic arthritis	12 (13)	29 (11)	1.1 (0.5 to 2.3)	1.3 (0.6 to 3.0)	0.8 (0.3 to 2.1)
Systemic autoimmune rheumatic disease	37 (18)	58 (10)	2.2 (1.4 to 3.5)	1.9 (1.0 to 3.5)	2.6 (1.5 to 4.5)
Antiphospholipid syndrome [†]	7 (27)	3 (4)	7.0 (1.8 to 27)	N/A	6.0 (1.5 to 24)
Sjögren's syndrome	16 (22)	24 (11)	2.4 (1.1 to 5.3)	2.4 (1.0 to 5.9)	2.5 (0.9 to 6.7)
Systemic lupus erythematosus [†]	3 (7)	17 (13)	0.5 (0.1 to 1.8)	N/A	0.9 (0.2 to 3.7)
Systemic sclerosis [†]	4 (14)	8 (9)	1.7 (0.4 to 6.8)	1.5 (0.3 to 7.2)	1.7 (0.4 to 7.9)
Vasculitis	78 (11)	173 (8)	1.4 (1.1 to 1.9)	1.4 (1.0 to 2.1)	1.6 (1.1 to 2.2)
ANCA-associated vasculitis [†]	6 (16)	13 (11)	1.5 (0.5 to 4.4)	1.6 (0.4 to 5.9)	2.1 (0.6 to 6.9)
Giant cell arteritis	9 (11)	21 (9)	1.3 (0.5 to 3.3)	1.3 (0.4 to 4.5)	1.3 (0.4 to 4.5)
Polymyalgia rheumatica	63 (10)	139 (8)	1.4 (1.0 to 2.0)	1.4 (0.9 to 2.1)	1.5 (1.1 to 2.2)

*Reference group was individuals with no sinusitis codes prior to index date. Adjusting for age, sex, electronic health record history, race and ethnicity, body mass index, smoking status. Bold values were statistically significant.
[†]Unadjusted conditional logistic regression due to small sample size.
 ANCA, antineutrophil cytoplasmic antibody; N/A, not applicable due to insufficient exposures.

smokers. These findings provide novel insights related to the pathogenesis of rheumatic diseases.

The first key and novel finding from this study was that sinusitis was associated with multiple incident rheumatic

diseases including APS, Sjögren's disease, seronegative RA and PMR. The association was strongest for systemic autoimmune rheumatic diseases including APS and Sjögren's disease, with history of sinusitis conferring

Table 3 Association between any preceding sinusitis and incident rheumatic disease, stratified by time of first sinusitis exposure

Rheumatic disease	Adjusted* OR (95% CI), years before index		
	>1 to 5 years (n=218)	>5 to 10 years (n=258)	>10 years (n=256)
Any rheumatic disease	1.5 (1.1 to 2.0)	1.7 (1.3 to 2.3)	1.2 (0.9 to 1.6)
Rheumatoid arthritis	1.6 (1.1 to 2.5)	1.2 (0.8 to 1.9)	1.1 (0.7 to 1.6)
Seropositive	1.4 (0.8 to 2.5)	1.1 (0.7 to 1.9)	1.0 (0.6 to 1.7)
Seronegative	2.0 (1.0 to 4.1)	1.3 (0.6 to 2.9)	1.2 (0.6 to 2.5)
Spondyloarthritis	1.0 (0.3 to 3.1)	2.2 (0.8 to 6.2)	1.2 (0.4 to 3.2)
Ankylosing spondylitis [†]	1.3 (0.1 to 13)	2.4 (0.3 to 18)	4.5 (0.4 to 55)
Psoriatic arthritis	0.9 (0.2 to 3.4)	2.2 (0.6 to 7.5)	0.8 (0.2 to 2.6)
Systemic autoimmune rheumatic disease	2.0 (0.9 to 4.3)	2.7 (1.3 to 5.7)	1.9 (0.9 to 4.2)
Antiphospholipid syndrome [†]	6.0 (1.1 to 33)	N/A	3.0 (0.2 to 48)
Sjögren's syndrome	2.0 (0.5 to 7.6)	3.2 (1.1 to 9.5)	2.0 (0.6 to 6.9)
Systemic lupus erythematosus [†]	0.5 (0.1 to 4.1)	0.7 (0.1 to 5.9)	0.4 (0.1 to 3.4)
Systemic sclerosis [†]	N/A	1.3 (0.1 to 14)	7.4 (0.7 to 74)
Vasculitis	1.1 (0.7 to 1.9)	2.0 (1.3 to 3.1)	1.0 (0.6 to 1.8)
ANCA-associated vasculitis [†]	0.4 (0.0 to 4.4)	3.5 (0.8 to 16)	1.1 (0.1 to 11)
Giant cell arteritis	2.0 (0.5 to 7.8)	1.2 (0.3 to 4.5)	0.4 (0.0 to 5.4)
Polymyalgia rheumatica	1.1 (0.6 to 2.0)	2.0 (1.3 to 3.2)	1.1 (0.6 to 2.0)

*Reference group was individuals with no sinusitis codes prior to index date. Adjusting for age, sex, electronic health record history, race and ethnicity, body mass index, smoking status. Bold values were statistically significant.
[†]Unadjusted conditional logistic regression due to small sample size.
 ANCA, antineutrophil cytoplasmic antibody; N/A, not applicable due to insufficient exposures.

Table 4 Association between any preceding sinusitis and incident rheumatic disease by number of sinusitis diagnosis codes

Rheumatic disease	Adjusted*OR for disease (95% CI)			P value
	1–3 codes (n=319)	4–6 codes (n=220)	7+ codes (n=193)	
Any rheumatic disease	1.3 (1.0 to 1.6)	1.5 (1.1 to 2.0)	1.7 (1.3 to 2.4)	<0.001
Rheumatoid arthritis	1.1 (0.8 to 1.6)	1.4 (0.9 to 2.1)	1.4 (0.9 to 2.2)	0.27
Seropositive	1.1 (0.7 to 1.8)	1.1 (0.6 to 1.9)	1.4 (0.8 to 2.4)	0.77
Seronegative	1.1 (0.5 to 2.2)	2.0 (1.0 to 4.2)	1.6 (0.7 to 3.3)	0.20
Spondyloarthritis	2.1 (0.8 to 5.0)	0.6 (0.1 to 3.5)	1.0 (0.3 to 3.0)	0.42
Ankylosing spondylitis [†]	3.0 (0.4 to 26)	1.0 (0.1 to 9.3)	7.2 (0.6 to 86)	0.80
Psoriatic arthritis	1.8 (0.7 to 4.9)	0.6 (0.0 to 8.9)	0.6 (0.2 to 2.2)	0.53
Systemic autoimmune rheumatic disease	1.7 (0.9 to 3.2)	2.0 (1.0 to 4.2)	4.8 (1.7 to 13)	0.004
Antiphospholipid syndrome [†]	21 (3.0 to 171)	N/A	N/A	N/A
Sjögren's syndrome	0.9 (0.2 to 3.3)	3.1 (1.0 to 9.4)	8.7 (1.4 to 52)	0.02
Systemic lupus erythematosus [†]	0.6 (0.1 to 2.9)	0.5 (0.1 to 4.0)	N/A	0.97
Systemic sclerosis [†]	1.2 (0.1 to 12)	0.9 (0.1 to 8.3)	6.1 (0.5 to 69)	0.87
Vasculitis	1.1 (0.7 to 1.8)	1.5 (0.9 to 2.4)	2.0 (1.2 to 3.4)	0.03
ANCA-associated vasculitis [†]	1.0 (0.2 to 5.2)	0.6 (0.1 to 5.6)	8.5 (0.9 to 83)	0.74
Giant cell arteritis	0.6 (0.1 to 2.7)	2.9 (0.7 to 13)	1.5 (0.1 to 16)	0.47
Polymyalgia rheumatica	1.2 (0.7 to 1.9)	1.5 (0.9 to 2.5)	1.8 (1.0 to 3.2)	0.12

*Reference group was individuals with no sinusitis codes prior to index date. Adjusting for age, sex, electronic health record history, race and ethnicity, body mass index, smoking status. Bold values were statistically significant. P values provided are 2 df p values from these models.
[†]Unadjusted conditional logistic regression due to small sample size.
 ANCA, antineutrophil cytoplasmic antibody; N/A, not applicable due to insufficient exposures.

over twofold increased risk of these diseases. Previous literature supports these associations. For example, prior studies showed an association between preceding sinusitis and ANCA-associated vasculitis¹⁶ and RA.^{14 15} In

addition, preceding infections are associated with both GCA^{18 19} and Sjögren's disease.²⁰ Furthermore, patients with rheumatic diseases including AS, myositis, RA, Sjögren's and SLE have increased risk of subsequent chronic sinusitis.^{39–41} By studying sinusitis at least 1-year prior to incident rheumatic disease, however, this study provides important evidence suggesting a true biological link.

One possible explanation for the observed association between sinusitis and rheumatic disease could be a shared immune defect that simultaneously predisposes to mucosal infection and breakdown of tolerance. For example, individuals with RA also have increased risk for allergic diseases.⁴² Similarly, sinusitis could represent an early manifestation of disease, as is already recognised for ANCA-associated vasculitis.¹⁶ However, the fact that the association was strongest in the 5–10 years before disease onset points away from these explanations. Unmeasured confounding such as from antibiotic exposure might also explain the association. However, the Nurses' Health Study showed no association between antibiotic use and RA.⁴³ In fact, certain antibiotics ameliorate rather than exacerbate APS,⁴⁴ AS⁴⁵ and RA⁴⁶ symptoms. A third explanation, therefore, could be that pathogenic organisms such as those involved in sinusitis play a causal role in disease. Indeed, both *Staphylococcus* and more recently *Corynebacterium* were implicated in pathogenesis of ANCA-associated vasculitis,⁴⁷ whereas *Ruminococcus gnavus* was associated with lupus nephritis,⁴⁸ RA⁴⁹ and spondyloarthritis.⁴⁹ Furthermore, sinusitis is associated with accelerated atherosclerosis, further supporting its potential inflammatory effects.⁵⁰ Therefore, future studies should

Table 5 Associations between any preceding sinusitis and incident rheumatic disease, stratified by smoking status

Rheumatic disease	Adjusted* OR for disease (95% CI)	
	Never smokers (n=2837)	Ever smokers (n=3806)
Any rheumatic disease	1.7 (1.3 to 2.2)	1.2 (1.0 to 1.6)
Rheumatoid arthritis	1.6 (1.1 to 2.4)	1.1 (0.8 to 1.5)
Seropositive	1.6 (1.0 to 2.7)	0.9 (0.6 to 1.4)
Seronegative	1.5 (0.7 to 2.9)	1.5 (0.8 to 2.8)
Spondyloarthritis	1.3 (0.5 to 3.7)	1.4 (0.6 to 3.1)
Ankylosing spondylitis [†]	2.2 (0.4 to 13)	2.6 (0.3 to 20)
Psoriatic arthritis	0.9 (0.2 to 3.4)	1.3 (0.5 to 3.1)
Systemic autoimmune rheumatic disease	2.3 (1.2 to 4.3)	2.1 (1.1 to 4.1)
Antiphospholipid syndrome [†]	N/A	1.7 (0.3,11)
Sjögren's syndrome	2.1 (0.7 to 6.1)	2.9 (1.0 to 8.2)
Systemic lupus erythematosus [†]	0.7 (0.1 to 3.9)	0.3 (0.0 to 2.6)
Systemic sclerosis [†]	3.4 (0.5 to 23)	1.3 (0.2 to 8.1)
Vasculitis	1.8 (1.2 to 2.7)	1.2 (0.8 to 1.8)
ANCA-associated vasculitis [†]	2.3 (0.4 to 14)	1.1 (0.3 to 4.1)
Giant cell arteritis	1.2 (0.4 to 4.1)	1.4 (0.3 to 5.6)
Polymyalgia rheumatica	1.8 (1.2 to 2.9)	1.1 (0.7 to 1.8)

*Reference group was individuals with no sinusitis codes prior to index date. Adjusting for age, sex, electronic health record history, race and ethnicity, body mass index, smoking status. Bold values were statistically significant.
[†]Unadjusted conditional logistic regression due to small sample size.

replicate the observed association between sinusitis and rheumatic diseases, search for additional causative organisms and determine whether preventing or treating sinusitis can prevent and/or treat rheumatic diseases.

A second key and novel finding from this study was that the association was strongest for sinusitis occurring 5–10 years before disease onset. For example, sinusitis occurring 5–10 years beforehand was associated with around threefold odds of Sjögren’s disease and ANCA-associated vasculitis (though the latter was not statistically significant). This finding fits with our hypothesis as well as a prior study of sinusitis and incident RA.¹⁵ Such timing argues against reverse causation (eg, Sjögren’s-related immune defects or dryness causing sinusitis) since sinusitis in the 1–5 years leading up to disease onset was less associated with these diseases. In addition, rheumatic disease autoantibodies including antinuclear antigen, ANCA, anti-CCP, RF and anti-Sjögren Syndrome (SS)A/B become detectable in nearly the same window, approximately 3–8 years before disease onset.^{51–54} On the other hand, sinusitis showed an elevated association with RA and APS in the 1–5 years window before disease. While this could reflect reverse causation, it could also point toward an infectious trigger. Indeed, infections are associated with RF⁵⁵ and antiphospholipid antibodies themselves and believed to play a causal role in APS based on evidence for molecular mimicry between APS-related peptides and common pathogens.⁴⁴

Another finding that points toward a true association was that increasing burden of sinusitis, as measured by number of codes, showed a dose-response association with disease. Prior studies of infections in Sjögren’s disease²⁰ and GCA¹⁹ also showed a dose-response association. In our study, the dose-response association was present for all diseases where a significant overall association was observed except PMR, including any rheumatic disease, systemic autoimmune rheumatic diseases, Sjögren’s disease and vasculitis. In addition, the dose-response association for acute sinusitis in seronegative RA suggests that the lack of association between sinusitis and overall RA in this study could have resulted from rule out codes, which would bias results towards the null. Other reasons, however, could include better capture of data for controls given the population-based design, different disease biology in different geographical regions or the smaller proportion of never smokers in this study (37%) compared with our previous study (50%).¹⁴

Indeed, a fourth key result from this study was that the association between sinusitis and incident rheumatic diseases was strongest among never smokers. One explanation for this finding could be chance alone, as the interaction p values were not significant. Another explanation to consider could be the ‘risk factor paradox,’ also called index event bias. Index event bias occurs from conditioning on the presence of an event (eg, RA), which induces an artificial negative association between its risk factors (eg, smoking and sinusitis).⁵⁶ A biological explanation, however, could be that both smoking and sinusitis

provide a similar and therefore redundant inflammatory trigger for disease. If true, the strong association between sinusitis and rheumatic disease among never smokers will become more relevant as smoking rates continue to decline.

Strengths of this study include its population-based design, manual verification of rheumatic diseases and their time of onset using validated classification criteria and relatively long duration of EHR history. However, there are several important limitations to consider. First, the findings may not generalise outside this single geographical region, especially since this population is predominately white and rheumatic disease outcomes are known to vary by race and ethnicity.⁵⁷ Second, results also may not generalise to all severities of sinusitis, as sinusitis that reaches medical care is more likely to be severe. Third, limited sample size limited power and precluded adjusted analysis for several rheumatic diseases of interest such as ANCA-associated vasculitis and APS. For example, sinusitis was not associated with GCA or SLE as we initially hypothesised, though the sample size was small and therefore CIs were wide for both. Fourth, some misclassification of sinusitis exposure is possible since sinusitis exposures were based on billing codes. However, sinusitis codes had 96% PPV by physician diagnosis in our study, and a 92% PPV in our previous study.¹⁴ Furthermore, misclassification of sinusitis exposure would bias results towards null. Fifth, reverse causation is possible where the rheumatic diseases themselves increase the risk of sinusitis. For example, disease-related symptoms begin a median of 7–24 days before RA criteria fulfilment,⁵⁸ 1.1 months before GCA criteria fulfilment²⁷ and 29 months before SLE criteria fulfilment⁵⁹ in our cohorts. To minimise this risk, we required sinusitis exposure to occur at least 1 year before disease onset. Sixth, unmeasured confounding is possible such as drug use (antibiotics, aspirin, non-steroidal anti-inflammatory drugs, anti-histamines), atopy, periodontitis⁶⁰ and healthcare utilisation. Finally, we performed multiple comparisons in this study, though each disease was prespecified in our protocol.

In summary, this study found that preceding history of sinusitis was associated with increased incidence of rheumatic diseases including APS, Sjögren’s disease, seronegative RA and PMR. These associations were strongest in the 5–10 years before disease onset, for the highest number of sinusitis codes and among never smokers. Overall, these findings point towards a role for sinus inflammation in the presentation, and possibly pathogenesis, of rheumatic disease.

Twitter Vanessa L Kronzer @KronzerMD, Jeffrey A Sparks @jeffsparks, Elena Myasoedova @MyasoedovaElena and Cynthia S Crowson @CrowsonCindy

Acknowledgements We thank all the participants and researchers involved with the Rochester Epidemiology Project for their support.

Contributors VK, ACH and CC had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: VK, JMD, ACH, JS, EM, AD-G, AM, MK, RV, KJW, KW and CC. Drafting of the manuscript: VK, ACH and CC. Critical revision of

the manuscript for important intellectual content: VK, JMD, ACH, JS, EM, AD-G, AMH, AM, MK, RV, KJW, KW and CC. Statistical analysis: ACH and CC. Obtained funding: VK and CC. Administrative, technical or material support: VK, ACH and CC. Supervision: JMD, JS, EM, AD-G, AMH, AM, MK, RV, KJW, KW and CC. VK and CC are responsible for the overall content as guarantors, accepting full responsibility for the finished work and/or the conduct of the study, having access to the data, and controlling the decision to publish.

Funding This study was supported by the Rheumatology Research Foundation Scientist Development Award (VLK), National Institute of Arthritis and Musculoskeletal and Skin Diseases award R01 AR46849 (CSC), and National Institute of Aging R01 AG068192 (EM). This study used the resources of the Rochester Epidemiology Project (REP) medical records-linkage system, which is supported by the National Institute on Aging (NIA; AG 058738), by the Mayo Clinic Research Committee, and by fees paid annually by REP users. JS is funded by NIH/NIAMS (grant numbers, R01 AR080659, R01 AR077607, P30 AR070253 and P30 AR072577), the R. Bruce and Joan M. Mickey Research Scholar Fund, and the Llura Gund Award for Rheumatoid Arthritis Research and Care. AD-G is funded by the Centers for Disease Control and Prevention (U01DP06491), the Rheumatology Research Foundation Scientist Development Award, the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, the Mayo Clinic Margaret Harvey Schering Clinician Career Development Award for Arthritis research and the Larry and Ruth Eaton Family Career Development Award in Innovative Arthritis Research.

Competing interests JS has received research support from Bristol Myers Squibb and performed consultancy for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Inova Diagnostics, Janssen, Optum, Pfizer and ReCor unrelated to this work. JMD has received research support from Pfizer, has licensed technology to Girihtet and Remission Medical and has provisional US patent application no. 63/243933 entitled, 'Methods and Materials for Assessing and Treating Arthritis'.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval Both the Mayo Clinic and Olmsted Medical Center Institutional Review Boards approved this study (20-008534; 046-omc-20). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Data are available upon reasonable request to the REP.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Vanessa L Kronzer <http://orcid.org/0000-0002-7489-3134>
 Jeffrey A Sparks <http://orcid.org/0000-0002-5556-4618>
 Elena Myasoedova <http://orcid.org/0000-0003-2006-1436>
 Kenneth J Warrington <http://orcid.org/0000-0001-7708-2487>
 Cynthia S Crowson <http://orcid.org/0000-0001-5847-7475>

REFERENCES

- Videm V, Cortes A, Thomas R, *et al*. Current smoking is associated with incident Ankylosing Spondylitis -- the HUNT population-based Norwegian health study. *J Rheumatol* 2014;41:2041–8.
- Brennan DN, Ungprasert P, Warrington KJ, *et al*. Smoking as a risk factor for giant cell arteritis: A systematic review and meta-analysis. *Semin Arthritis Rheum* 2018;48:S0049-0172(17)30839-9:529–37..
- Chinoy H, Adimulam S, Marriage F, *et al*. Interaction of HLA-Drb1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory Myopathies: a European-wide case study. *Ann Rheum Dis* 2012;71:961–5.
- Li W, Han J, Qureshi AA. Smoking and risk of incident Psoriatic arthritis in US women. *Ann Rheum Dis* 2012;71:804–8.
- Stolt P, Bengtsson C, Nordmark B, *et al*. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. *Ann Rheum Dis* 2003;62:835–41.
- Costenbader KH, Kim DJ, Peerzada J, *et al*. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. *Arthritis Rheum* 2004;50:849–57.
- Gómez-Puerta JA, Gedmintas L, Costenbader KH. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. *Autoimmun Rev* 2013;12:S1568-9972(13)00120-1:1129–35..
- Stolt P, Källberg H, Lundberg I, *et al*. Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study. *Ann Rheum Dis* 2005;64:582–6.
- Parks CG, Cooper GS, Nylander-French LA, *et al*. Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States. *Arthritis Rheum* 2002;46:1840–50.
- Marie I, Gehanno J-F, Bubenheim M, *et al*. Prospective study to evaluate the association between systemic sclerosis and occupational exposure and review of the literature. *Autoimmun Rev* 2014;13:S1568-9972(13)00177-8:151–6..
- Hart JE, Källberg H, Laden F, *et al*. Ambient air pollution exposures and risk of rheumatoid arthritis: results from the Swedish EIRA case-control study. *Ann Rheum Dis* 2013;72:888–94.
- Ilar A, Gustavsson P, Wiebert P, *et al*. Occupational exposure to organic dusts and risk of developing rheumatoid arthritis: findings from a Swedish population-based case-control study. *RMD Open* 2019;5:e001049.
- Kronzer VL, Westerlind H, Alfredsson L, *et al*. Respiratory diseases as risk factors for Seropositive and Seronegative rheumatoid arthritis and in relation to smoking. *Arthritis Rheumatol* 2021;73:61–8.
- Kronzer VL, Huang W, Zaccardelli A, *et al*. Association of sinusitis and upper respiratory tract diseases with incident rheumatoid arthritis: A case-control study. *J Rheumatol* 2022;49:358–64.
- Kronzer VL, Huang W, Crowson CS, *et al*. Timing of sinusitis and other respiratory tract diseases and risk of rheumatoid arthritis. *Semin Arthritis Rheum* 2022;52:S0049-0172(21)00229-8:151937..
- Albert D, Clarkin C, Komoroski J, *et al*. Wegener's granulomatosis: possible role of environmental agents in its pathogenesis. *Arthritis Rheum* 2004;51:656–64.
- Svensson J, Holmqvist M, Lundberg IE, *et al*. Infections and respiratory tract disease as risk factors for idiopathic inflammatory Myopathies: a population-based case-control study. *Ann Rheum Dis* 2017;76:1803–8.
- Russo MG, Waxman J, Abdoh AA, *et al*. Correlation between infection and the onset of the giant cell (temporal) arteritis syndrome. A trigger mechanism *Arthritis Rheum* 1995;38:374–80.
- Rhee RL, Grayson PC, Merkel PA, *et al*. Infections and the risk of incident giant cell arteritis: a population-based, case-control study. *Ann Rheum Dis* 2017;76:1031–5.
- Mofors J, Arkema EV, Björk A, *et al*. Infections increase the risk of developing Sjögren's syndrome. *J Intern Med* 2019;285:670–80.
- Cooper GS, Dooley MA, Treadwell EL, *et al*. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. *J Clin Epidemiol* 2002;55:982–9.
- St Sauver JL, Grossardt BR, Yawn BP, *et al*. Data resource profile: the Rochester epidemiology project (REP) medical records-linkage system. *International Journal of Epidemiology* 2012;41:1614–24.
- Berti A, Cornec D, Crowson CS, *et al*. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota: A twenty-year US population-based study. *Arthritis & Rheumatology* 2017;69:2338–50. 10.1002/art.40313 Available: <https://acrjournals.onlinelibrary.wiley.com/toc/23265205/69/12>
- Duarte-García A, Pham MM, Crowson CS, *et al*. The epidemiology of Antiphospholipid syndrome: A population-based study. *Arthritis & Rheumatology* 2019;71:1545–52. 10.1002/art.40901 Available: <https://acrjournals.onlinelibrary.wiley.com/toc/23265205/71/9>
- Wright KA, Crowson CS, Michet CJ, *et al*. Time trends in incidence, clinical features, and cardiovascular disease in Ankylosing Spondylitis over three decades: a population-based study. *Arthritis Care Res (Hoboken)* 2015;67:836–41.
- Kronzer VL, Kimbrough BA, Crowson CS, *et al*. Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study. *Arthritis Care Res (Hoboken)* September 21, 2021.
- Garvey TD, Koster MJ, Crowson CS, *et al*. Incidence, survival, and diagnostic trends in GCA across seven decades in a North American population-based cohort. *Semin Arthritis Rheum* 2021;51:S0049-0172(21)00186-4:1193–9..

- 28 Ungprasert P, Crowson CS, Chowdhary VR, *et al.* Epidemiology of mixed connective tissue disease, 1985-2014: A population-based study. *Arthritis Care Res (Hoboken)* 2016;68:1843-8.
- 29 Raheel S, Shbeeb I, Crowson CS, *et al.* Epidemiology of Polymyalgia Rheumatica 2000-2014 and examination of incidence and survival trends over 45 years: A population-based study. *Arthritis Care & Research* 2017;69:1282-5. 10.1002/acr.23132 Available: <https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.23132>
- 30 Karmacharya P, Crowson CS, Bekele D, *et al.* The epidemiology of Psoriatic arthritis over five decades: A population-based study. *Arthritis Rheumatol* 2021;73:1878-85.
- 31 Myasoedova E, Davis J, Matteson EL, *et al.* Is the epidemiology of rheumatoid arthritis changing? results from a population-based incidence study, 1985-2014. *Ann Rheum Dis* 2020;79:440-4.
- 32 Duarte-García A, Hocaoglu M, Valenzuela-Almada M, *et al.* Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades. *Ann Rheum Dis* 2022;annrheumdis-2022-222276.
- 33 Maciel G, Crowson CS, Matteson EL, *et al.* Incidence and mortality of physician-diagnosed primary Sjögren syndrome: time trends over a 40-year period in a population-based US cohort. *Mayo Clin Proc* 2017;92:S0025-6196(17)30116-7:734-43..
- 34 Coffey CM, Radwan YA, Sandhu AS, *et al.* Epidemiology and trends in survival of systemic sclerosis in Olmsted County (1980-2018): A population-based study. *J Scleroderma Relat Disord* 2021;6:264-70.
- 35 Kronzer VL, Tarabochia AD, Lobo Romero AS, *et al.* Lack of Association of spontaneous coronary artery dissection with autoimmune disease. *J Am Coll Cardiol* 2020;76:S0735-1097(20)37187-4:2226-34..
- 36 Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, *et al.* Clinical practice guideline (update): adult sinusitis. *Otolaryngol--Head Neck Surg* 2015;152:S1-39.
- 37 Wallace DV, Dykewicz MS, Bernstein DI, *et al.* The diagnosis and management of rhinitis: an updated practice parameter. *J Allergy Clin Immunol* 2008;122(2 Suppl):S1-84.
- 38 Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. *Ann Intern Med* 1993;118:201-10.
- 39 Shih L-C, Hsieh H-H, Tsay GJ, *et al.* Chronic Rhinosinusitis and Premorbid autoimmune diseases: a population-based case-control study. *Sci Rep* 2020;10:18635.
- 40 Chang G-H, Chen Y-C, Lin K-M, *et al.* Real-world database examining the association between Sjögren's syndrome and chronic Rhinosinusitis. *J Clin Med* 2019;8:155.
- 41 Michaud K, Wolfe F. The Association of rheumatoid arthritis and its treatment with sinus disease. *J Rheumatol* 2006;33:2412-5.
- 42 Kronzer VL, Crowson CS, Sparks JA, *et al.* Investigating asthma, allergic disease, passive smoke exposure, and risk of rheumatoid arthritis. *Arthritis & Rheumatology* 2019;71:1217-24. 10.1002/art.40858 Available: <https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.40858>
- 43 Liu Y, Xia B, Li B, *et al.* No association between recent antibiotic use and risk of rheumatoid arthritis: results from two prospective cohort studies. *Expert Opinion on Drug Safety* 2022;21:121-6.
- 44 Shoenfeld Y, Blank M, Cervera R, *et al.* Infectious origin of the Antiphospholipid syndrome. *Ann Rheum Dis* 2006;65:2-6.
- 45 Ogrendik M. Treatment of Ankylosing Spondylitis with Moxifloxacin. *Southern Medical Journal* 2007;100:366-70.
- 46 Stone M, Fortin PR, Pacheco-Tena C, *et al.* Should Tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. *J Rheumatol* 2003;30:2112-22.
- 47 Rhee RL, Lu J, Bittinger K, *et al.* Dynamic changes in the nasal Microbiome associated with disease activity in patients with granulomatous polyangiitis. *Arthritis Rheumatol* 2021;73:1703-12.
- 48 Azzouz D, Omarbekova A, Heguy A, *et al.* Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut Commensal. *Ann Rheum Dis* 2019;78:947-56.
- 49 Thompson KN, Bonham KS, Ilott NE, *et al.* Alterations in the gut Microbiome implicate key Taxa and metabolic pathways across inflammatory arthritis phenotypes. *Sci Transl Med* 2023;15:eabn4722:706..
- 50 Elcioglu OC, Afsar B, Bakan A, *et al.* Chronic Rhinosinusitis, endothelial dysfunction, and Atherosclerosis. *Am J Rhinol Allergy* 2016;30:58-61.
- 51 Berglin E, Mohammad AJ, Dahlqvist J, *et al.* Anti-neutrophil cytoplasmic antibodies Predate symptom onset of ANCA-associated vasculitis. A case-control study. *J Autoimmun* 2021;117:S0896-8411(20)30212-2:102579..
- 52 Eriksson C, Kokkonen H, Johansson M, *et al.* Autoantibodies Predate the onset of systemic lupus erythematosus in northern Sweden. *Arthritis Res Ther* 2011;13:R30.
- 53 Theander E, Jonsson R, Sjöström B, *et al.* Prediction of Sjögren's syndrome years before diagnosis and identification of patients with early Onset and severe disease course by autoantibody profiling. *Arthritis Rheumatol* 2015;67:2427-36.
- 54 Nielen MMJ, van Schaardenburg D, Reesink HW, *et al.* Specific Autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. *Arthritis Rheum* 2004;50:380-6.
- 55 Stevenson DL, Harris AG, Neal KR, *et al.* The presence of rheumatoid factor in sera from anti-HCV positive blood donors interferes with the detection of HCV-specific IgM. *J Hepatol* 1996;25:621-6.
- 56 Choi HK, Nguyen U-S, Niu J, *et al.* Selection bias in rheumatic disease research. *Nat Rev Rheumatol* 2014;10:403-12.
- 57 Gianfrancesco MA, Leykina LA, Izadi Z, *et al.* Association of race and Ethnicity with COVID-19 outcomes in rheumatic disease: data from the COVID-19 global rheumatology alliance physician Registry. *Arthritis Rheumatol* 2021;73:374-80.
- 58 Coffey CM, Crowson CS, Myasoedova E, *et al.* Evidence of diagnostic and treatment delay in Seronegative rheumatoid arthritis: missing the window of opportunity. *Mayo Clin Proc* 2019;94:S0025-6196(19)30505-1:2241-8..
- 59 Duarte-García A, Hocaoglu M, Osei-Onomah S-A, *et al.* Population-based incidence and time to classification of systemic lupus erythematosus by three different classification criteria: a lupus Midwest network (LUMEN) study. *Rheumatology (Oxford)* 2022;61:2424-31.
- 60 Kim MG, Kang MG, Lee MG, *et al.* Periodontitis is associated with the development of fungal sinusitis: A nationwide 12-year follow-up study. *J Clin Periodontol* 2023;50:440-51.